Gilead Sciences (Nasdaq: GILD) subsidiary company Kite has announced the publication of a new European analysis of commercial manufacturing experience of Yescarta (axicabtagene ciloleucel).
The analysis shows a median European manufacturing turnaround time of 19 days for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) during a period from 2020 to 2022. This compares to 25 days from the initial two-year analysis from 2018 to 2022.
An improvement in delivery success rate since the initial two-year period was also observed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze